Camurus Q2 2025: Deal with Eli Lilly - Redeye

Redeye comments on Camurus' Q2 report 2025, which was in line with our estimates on a constant currency basis. The main events that increase our base case are the deal with Eli Lilly and the positive phase II results of CAM2029 in polycystic liver disease.

Länk till analysen i sin helhet: https://www.redeye.se/research/1119087/camurus-q2-2025-deal-with-eli-lilly?utm_source=finwire&utm_medium=RSS